And I'd consider that increase in valuation somewhat low if...

And I'd consider that increase in valuation somewhat low if the drug is capable of doing what it's supposed to. $1 billion? If AGN licenses the drug for stroke in the American market, I'd be confident they could attain $2 billion+ valuation with significant royalties. I'm thinking at least 20-25% such is the potential upside. If she's talking about the value increasing 10 fold due to the inflection point reached post Phase 2 top line data results, that's probably more on the money.

Encouraging to hear Liz thinks they are still on track for an 18 month duration for the trial.